Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract in dogs and are also recognized in cats. They arise from the interstitial cells of Cajal (ICC), which are pacemaker cells that regulate gastrointestinal motility. GISTs are characterized by the expression of the receptor tyrosine kinase KIT (CD117) and, in many cases, mutations in the KIT or PDGFRA genes. In veterinary medicine, GISTs are typically well-circumscribed, often ulcerated masses that can occur anywhere along the GI tract, with a predilection for the stomach and cecum in dogs, and the small intestine in cats. They are generally considered to have malignant potential, but their biological behavior varies from benign to highly aggressive, with metastasis most commonly to the liver and regional lymph nodes. Accurate diagnosis is crucial because GISTs respond to tyrosine kinase inhibitors (TKIs) such as imatinib, whereas other sarcomas do not.

The exact etiology of GISTs in veterinary species is not fully understood, but it is believed to involve spontaneous or acquired mutations in the KIT gene (encoding the KIT receptor tyrosine kinase) or, less commonly, the PDGFRA gene. These mutations lead to constitutive activation of the receptor, promoting uncontrolled cell proliferation and survival. In dogs, mutations are most frequently found in exon 11 of KIT, with less common mutations in exons 9, 13, and 17. In cats, similar mutations have been identified, but the prevalence is lower. No specific viral, bacterial, or environmental causes have been identified. Genetic predisposition is suspected in certain breeds, but no direct hereditary pattern has been established. Chronic inflammation or prior radiation exposure are theoretical risk factors but have not been confirmed.

GISTs are relatively uncommon in dogs and cats, accounting for approximately 1-3% of all canine GI tumors and a slightly higher percentage in cats. They are most commonly diagnosed in middle-aged to older animals, with a median age of 10-12 years in dogs and 10-12 years in cats. No strong sex predilection is reported, though some studies suggest a slight male predominance in dogs. Breed predispositions in dogs include Boxers, Boston Terriers, Golden Retrievers, and Labrador Retrievers, but any breed can be affected. In cats, domestic shorthair cats are most commonly represented. There is no geographic or seasonal variation reported.

GISTs originate from the interstitial cells of Cajal (ICC), which are located in the myenteric plexus and are responsible for generating slow waves that coordinate peristalsis. The hallmark of GIST is the presence of activating mutations in the KIT or PDGFRA genes, leading to ligand-independent dimerization and autophosphorylation of the receptor, which triggers downstream signaling pathways including the RAS/MAPK, PI3K/AKT, and STAT pathways. This results in uncontrolled cell proliferation, resistance to apoptosis, and altered cell adhesion. The tumor grows as a well-circumscribed, often extramural mass that can compress adjacent structures, cause luminal obstruction, or ulcerate, leading to chronic blood loss and anemia. Malignant GISTs can invade locally and metastasize hematogenously, most commonly to the liver and peritoneum, and less frequently to the lungs and bone. The biological behavior is variable, and histologic features such as mitotic index, cellularity, and necrosis are used to predict malignancy.

Predisposing factors for GISTs in dogs and cats are not well-defined, but include advanced age, as most tumors occur in older animals. Certain breeds, such as Boxers and Boston Terriers, may have a genetic predisposition, possibly due to inherited mutations in KIT or other genes. Chronic gastrointestinal inflammation or previous abdominal radiation therapy are theoretical risk factors. Immunosuppression has not been directly linked to GIST development. No dietary or environmental factors have been confirmed.

Clinical signs of GISTs are often nonspecific and depend on the tumor location and size. Common signs include chronic vomiting, diarrhea, weight loss, anorexia, lethargy, and abdominal pain. Melena or hematochezia may occur due to mucosal ulceration. In some cases, a palpable abdominal mass may be detected. Large tumors can cause partial or complete intestinal obstruction, leading to acute onset of vomiting, abdominal distension, and constipation. Perforation can result in peritonitis and acute abdomen. In cats, signs may be more subtle, with weight loss and vomiting being the most frequent findings. Anemia due to chronic blood loss is common and may manifest as pale mucous membranes and weakness.

Differential diagnoses for GISTs include other gastrointestinal mesenchymal tumors such as leiomyoma, leiomyosarcoma, and other sarcomas (e.g., fibrosarcoma, hemangiosarcoma). Epithelial tumors like adenocarcinoma and neuroendocrine tumors (carcinoids) can also present similarly. Inflammatory bowel disease, foreign body obstruction, intussusception, and granulomatous enteritis may mimic the clinical signs. Lymphoma, especially in cats, is a common differential. For cecal masses, typhlitis or cecal inversion should be considered. Diagnostic differentiation relies on histopathology with immunohistochemistry (IHC): GISTs are typically positive for KIT (CD117) and often positive for CD34, while leiomyosarcomas are positive for smooth muscle actin (SMA) and desmin, and schwannomas are positive for S100. PCR for KIT mutations can also help confirm the diagnosis.

The diagnostic approach to a suspected GIST begins with a thorough history and physical examination, including a rectal exam. Baseline bloodwork (CBC, biochemistry, urinalysis) and abdominal imaging (radiography and ultrasonography) are recommended. Abdominal ultrasound is highly sensitive for detecting GI masses and can assess for metastasis. If a mass is identified, fine-needle aspiration (FNA) may be attempted, but cytology is often nondiagnostic for mesenchymal tumors due to poor exfoliation. Definitive diagnosis requires histopathology via surgical biopsy or endoscopic biopsy. Immunohistochemistry is essential to differentiate GIST from other sarcomas. If surgery is planned, staging with thoracic radiographs and abdominal ultrasound (or CT) is recommended to rule out metastasis. In cases where surgery is not feasible, a preoperative biopsy (e.g., ultrasound-guided core biopsy) may be obtained to guide medical therapy with TKIs.

Complete blood count (CBC) may reveal anemia (regenerative or non-regenerative) due to chronic blood loss, and occasionally leukocytosis or thrombocytosis. Serum biochemistry may show hypoalbuminemia due to protein-losing enteropathy, and elevated liver enzymes if hepatic metastasis is present. Electrolyte imbalances (e.g., hypokalemia) may occur with chronic vomiting. Urinalysis is usually unremarkable. Specific biomarkers for GIST are not available in veterinary medicine. Fecal occult blood testing may be positive. In cases with suspected metastasis, liver enzyme evaluation and possibly bile acid testing are warranted.

Abdominal radiographs may reveal a soft tissue mass or signs of intestinal obstruction, but are often nonspecific. Abdominal ultrasonography is the imaging modality of choice, typically showing a well-defined, hypoechoic, heterogeneous mass arising from the GI wall, often with a target-like appearance. Doppler ultrasound may show increased vascularity. Ultrasonography is also useful for detecting hepatic metastasis and abdominal lymphadenopathy. Computed tomography (CT) provides better characterization of the mass, its relationship to adjacent structures, and staging of metastasis, and is recommended for surgical planning. MRI is rarely used but can be helpful for evaluating pelvic or perineal masses. Endoscopy may be useful for gastric or duodenal masses, allowing direct visualization and biopsy, but may not reach distal small intestinal tumors.

Cytology from FNA is often nondiagnostic due to the cohesive nature of spindle cells, but may show clusters of spindle cells with moderate anisocytosis. Histopathology is the gold standard for diagnosis. Grossly, GISTs are typically well-circumscribed, firm, white to tan masses that may be ulcerated. Microscopically, they are composed of spindle cells (less commonly epithelioid) arranged in interlacing fascicles or whorls. Nuclear pleomorphism and mitotic count are variable. Immunohistochemistry is essential: GISTs are positive for KIT (CD117) in >90% of cases, and often positive for CD34, while negative for SMA, desmin, and S100. Mutational analysis of KIT and PDGFRA can be performed on paraffin-embedded tissue to guide therapy and predict response to TKIs.

Surgical resection with wide margins is the treatment of choice for localized GISTs. Complete surgical excision (R0) is associated with a better prognosis. For tumors that are not completely resectable or have metastasized, tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (Glivec) are used. In dogs, imatinib is dosed at 10 mg/kg PO q24h, and in cats at 5-10 mg/kg PO q24h. Toceranib phosphate (Palladia) is another TKI that has shown efficacy in canine GISTs, dosed at 2.75-3.25 mg/kg PO q48h (or three times weekly). These drugs are generally well-tolerated but can cause gastrointestinal upset, neutropenia, and hepatotoxicity. Supportive care includes fluid therapy, antiemetics (e.g., maropitant 1 mg/kg IV/SC q24h or 2 mg/kg PO q24h), and nutritional support. In cases of severe anemia, blood transfusion may be necessary. Chemotherapy with conventional agents (e.g., doxorubicin) has limited efficacy and is not routinely recommended.

The prognosis for GISTs is variable and depends on tumor size, mitotic index, presence of necrosis, and completeness of surgical excision. In dogs, the median survival time after surgical resection is approximately 2-3 years, with a 1-year survival rate of about 80% and 2-year survival of 60%. Tumors with a mitotic count >5 per 10 high-power fields (HPF) are associated with a worse prognosis. Metastatic disease at diagnosis carries a poor prognosis, with median survival of less than 1 year. In cats, the prognosis is generally poorer, with a median survival of around 1 year. Response to TKI therapy can improve survival in cases with KIT mutations, but resistance may develop over time.

After surgical resection, patients should be re-examined every 3 months for the first year, then every 6 months thereafter. Serial abdominal ultrasound is recommended to monitor for local recurrence or metastasis. Complete blood count and serum biochemistry should be performed at each recheck. If the patient is on TKI therapy, bloodwork should be monitored monthly for the first 3 months, then every 3 months, to assess for neutropenia, thrombocytopenia, and hepatotoxicity. Dose adjustments may be necessary based on toxicity. In cases of incomplete resection or metastatic disease, imaging (ultrasound or CT) should be repeated every 3-6 months to assess tumor response.

Pearls: 1) Always include GIST in the differential for a GI mass in older dogs and cats, especially if the mass is well-circumscribed and extramural. 2) Immunohistochemistry is essential for definitive diagnosis; KIT positivity confirms GIST. 3) Surgical resection with clean margins offers the best chance for cure. 4) TKIs like imatinib or toceranib can be effective for incompletely resected or metastatic GISTs, especially if KIT mutations are present. 5) Mitotic count is the most important prognostic indicator. Pitfalls: 1) FNA cytology is often nondiagnostic; do not rely on it to rule out GIST. 2) Do not confuse GIST with leiomyosarcoma; they have different treatments and prognoses. 3) Avoid incomplete resection; if margins are dirty, consider re-excision or TKI therapy. 4) Do not use conventional chemotherapy as first-line treatment; it is ineffective. 5) Monitor for TKI side effects, especially neutropenia and hepatotoxicity.

1) Imatinib mesylate (Glivec): Dogs: 10 mg/kg PO q24h. Cats: 5-10 mg/kg PO q24h. Administer with food to reduce GI upset. Monitor CBC and liver enzymes monthly for the first 3 months, then every 3 months. Dose reduction or discontinuation may be needed if neutropenia (ANC < 1500/µL) or hepatotoxicity occurs. 2) Toceranib phosphate (Palladia): Dogs: 2.75-3.25 mg/kg PO q48h (or three times weekly). Cats: 2.75 mg/kg PO q48h (off-label). Administer on an empty stomach. Monitor for GI toxicity, neutropenia, and proteinuria. Dose adjustments are based on toxicity. 3) Supportive care: Maropitant (Cerenia) 1 mg/kg IV/SC q24h or 2 mg/kg PO q24h for vomiting. Omeprazole 0.7-1 mg/kg PO q24h for gastric ulceration. Sucralfate 0.5-1 g PO q8h for GI protection. For anemia, consider packed red blood cell transfusion if PCV < 20% with clinical signs. 4) Analgesia: For post-operative pain, use opioids such as buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h or fentanyl CRI at 2-5 µg/kg/h. NSAIDs should be avoided due to GI ulceration risk.

The veterinary literature on GISTs is limited but growing. A landmark study by Frost et al. (2003) described the clinicopathologic features of GISTs in dogs and cats, highlighting KIT expression and the presence of KIT mutations. Another study by Kobayashi et al. (2012) evaluated the efficacy of imatinib in dogs with GIST, showing a response rate of approximately 70% in tumors with KIT mutations. A more recent study by London et al. (2012) demonstrated that toceranib has activity against GISTs, with a clinical benefit rate of 60%. Consensus guidelines from the Veterinary Society of Surgical Oncology (VSSO) recommend surgical resection as the primary treatment, with TKI therapy reserved for incompletely resected or metastatic tumors. The ACVIM consensus statement on the diagnosis and treatment of GI tumors (2019) emphasizes the importance of immunohistochemistry for accurate diagnosis and the use of mitotic count for prognostication. Overall, the evidence supports the use of TKIs in the management of GISTs, but prospective randomized trials are needed to establish optimal protocols.